作者: Charles Swanton , Carlos Caldas , None
DOI: 10.1111/J.1749-6632.2010.05776.X
关键词:
摘要: Despite rapid progress in annotating the human genome, biomarker discovery has been limited, part, due to restricted adoption of analysis clinical trials. In this short review we present a roadmap drive field personalized cancer management and patient stratification. We suggest that improved understanding disease biology drug response advance trial design would enable novel biomarkers be identified prospectively evaluated during early phase trials; there will also value banked material from completed trials identify validate biomarkers. Such requires standardized tissue collection protocols, bioinformatics strategies integrated with functional genomics analysis, next generation sequencing technologies. argue failure adopt these methods rapidly into increase late stage attrition, waste resources, risk harm within unselected cohorts.